Most Read

The future that TED Talks have long promised is one step closer to reality, thanks to a new deal between pharmaceutical giant GlaxoSmithKline (GSK) and home DNA-testing kit service 23andMe.

The four-year agreement will grant GSK exclusive access to 23andMe’s database of genetic information, with the goal of developing new, targeted drugs and therapies. This isn’t the first time that 23andMe has offered its customers’ data to another organization for research, but those partnerships have previously been transparent. What does this new deal mean for genetic privacy and who will benefit from the partnership?

Keep reading... Show less